Ventricular, paraventricular and circumventricular structures involved in peptide-induced satiety.
Cholecystokinin, bombesin or gastrin (2 microliter of 50 ng/microliter) was injected stereotaxically into the paraventricular nucleus of the hypothalamus, the arcuate/ventromedial area, the subfornical organ, the area postrema and the cerebral aqueduct of Sprague-Dawley rats and the effects of these injections on food and water intake were studied. While the injection of cholecystokinin reduced food intake when it was injected into both hypothalamic loci, food and water intake were most severely affected by the injection of this peptide into the cerebral aqueduct. Bombesin reduced food intake after its injection into all areas except the subfornical organ and reliable reductions in water intake were seen after injection of this peptide into all areas except the paraventricular nucleus. Minor reductions in food intake were seen following gastrin injection into the paraventricular nucleus while increased water consumption was observed after this peptide was injected into the paraventricular nucleus and cerebral aqueduct. In a second study 6-hydroxydopamine injections (2 microliter of 8 micrograms/microliter were made into the five areas studied 10 days before animals were injected with 100 micrograms/kg of cholecystokinin (i.p.). All 6-hydroxydopamine-injected animals reduced their food and water intake in response to the cholecystokinin challenge as did intact controls. These results indicate that while the changes in food and water intake produced by the central injection of cholecystokinin, bombesin or gastrin may involve central catecholamine systems, those occurring after its systemic administration do not. Therefore, if the release of gastrointestinal peptides during natural feeding is part of a homeostatic mechanism regulating hunger and satiety, this mechanism may operate without directly involving central catecholamine systems.
D000818:Animals; D001111:Arcuate Nucleus of Hypothalamus / Q000187:drug effects; D001839:Bombesin / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000502:physiology; D002535:Cerebral Aqueduct / Q000187:drug effects; D005755:Gastrins / Q000494:pharmacology; D006892:Hydroxydopamines / Q000494:pharmacology; D008297:Male; D016627:Oxidopamine; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects; D010455:Peptides / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012527:Satiation / Q000187:drug effects* / Q000502:physiology; D012844:Sincalide / Q000494:pharmacology; D013356:Subfornical Organ / Q000187:drug effects; D014697:Ventromedial Hypothalamic Nucleus / Q000187:drug effects
D005755:Gastrins; D006892:Hydroxydopamines; D010455:Peptides; D016627:Oxidopamine; D012844:Sincalide; D001839:Bombesin